What is ASP9831 used for?

ASP9831 is indicated for Treatment of autoimmune hemolytic anemia.

ASP9831 is developed by Astellas Pharma Inc.

What are the side effects of ASP9831?

Common side effects include Increased risk of infections.

Last reviewed 2026-04-23 · How we verify

ASP9831

Astellas Pharma Inc · Phase 2 active Small molecule

ASP9831 is a small molecule inhibitor of the PI3K delta subunit.

ASP9831 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of autoimmune hemolytic anemia.

At a glance

Generic name	ASP9831
Sponsor	Astellas Pharma Inc
Drug class	PI3K delta inhibitor
Target	PI3K delta
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

By inhibiting PI3K delta, ASP9831 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.

Approved indications

Treatment of autoimmune hemolytic anemia

Common side effects

Increased risk of infections

Key clinical trials

A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASP9831 CI brief — competitive landscape report
ASP9831 updates RSS · CI watch RSS
Astellas Pharma Inc portfolio CI